GlassScriptPhysician profile
Garrett Furth
NPI 1225730807
$7,090.12
in general payments reported to CMS, 2019-2025
23 companies · $5,462 in 2025
The $5,462 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,628 · 2025: $5,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,949 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,949.12 |
| Education | $141.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,192.32 | 2024-2025 | |
| Abbvie INC. | $1,157.29 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $970.26 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $638.26 | 2024-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $315.22 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $310.59 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $255.51 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $231.85 | 2024-2025 | Ebglyss, Taltz |
| Dermavant Sciences, INC. | $220.92 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $208.95 | 2024-2025 | Sotyktu |
| Blueprint Medicines Corporation | $185.02 | 2024-2025 | Ayvakit |
| Incyte Corporation | $154.42 | 2025 | Opzelura |
| Amgen INC. | $153.82 | 2025 | Otezla |
| Johnson & Johnson Health Care Systems INC. | $149.62 | 2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $146.31 | 2025 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $129.72 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $120.91 | 2024-2025 | Cabtreo, Siliq |
| Biofrontera INC. | $115.80 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.09 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $102.35 | 2025 | |
| Organon LLC | $90.12 | 2025 | Vtama |
| Janssen Biotech, INC. | $86.94 | 2025 | Tremfya, Simponi, Stelara |
| Almirall LLC | $42.83 | 2025 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Furth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.